Common CRAMER on ISIS .....GENZYME SHARE HOLDERS KNOWS
Kynamro, co-developed by Isis and Sanofi unit Genzyme, is intended to reduce bad cholesterol in patients with a lipid disorder, who are already on a stable regimen of lipid-lowering therapies but require additional treatment.
The disorder, called familial hypercholesterolemia, is a genetic disease that results in elevated bad cholesterol levels and increased risk of premature heart disease.
The FDA reviewers said Kynamro was highly effective in reducing bad cholesterol over 26 weeks according to both their analyses and data submitted by the companies.
there are very few patients to be used this drug in american,you said genetic diseas is not common along in populations. I'll stand by untill ISIS pull back to $5 other wise money lose in any moment by hedge funds shorting it. this is cramer's bullish stock in a week ago when it was hitting $14/s. not good for long hold at price above$8.